Virginia L. Kan
YOU?
Author Swipe
View article: SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial)
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial) Open
View article: Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial Open
View article: Associations of functional human leucocyte antigen class I groups with HIV viral load in a heterogeneous cohort
Associations of functional human leucocyte antigen class I groups with HIV viral load in a heterogeneous cohort Open
Objective: Human leucocyte antigen (HLA) class I alleles are the main host genetic factors involved in controlling HIV-1 viral load (VL). Nevertheless, HLA diversity has proven a significant challenge in association studies. We assessed ho…
View article: Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection
Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection Open
Among adults with CD4+ counts >500 cells/mm3, excess risk of AIDS and SNA associated with delaying treatment initiation was diminished after ART initiation, but persistent excess risk remained. (Funded by the National…
View article: Deep-sequencing of viral genomes from a large and diverse cohort of treatment-naive HIV-infected persons shows associations between intrahost genetic diversity and viral load
Deep-sequencing of viral genomes from a large and diverse cohort of treatment-naive HIV-infected persons shows associations between intrahost genetic diversity and viral load Open
Background Infection with human immunodeficiency virus type 1 (HIV) typically results from transmission of a small and genetically uniform viral population. Following transmission, the virus population becomes more diverse because of recom…
View article: LB2305. Long Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection: Findings from the Extended Follow-up of the START Trial
LB2305. Long Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection: Findings from the Extended Follow-up of the START Trial Open
Background Deferral of antiretroviral therapy (ART) initiation until CD4 count < 350 cells/μL in people with CD4 > 500 increases risk of AIDS and serious non-AIDS (SNA) conditions. Evidence from randomized trials is lacking to assess…
View article: The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19 Open
U.S. government Operation Warp Speed and National Institute of Allergy and Infectious Diseases.
View article: Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 Open
National Institutes of Health.
View article: Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO)
Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO) Open
View article: Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial Open
View article: Associations of functional HLA class I groups with HIV viral load in a heterogeneous cohort
Associations of functional HLA class I groups with HIV viral load in a heterogeneous cohort Open
Human Leucocyte Antigen (HLA) class I alleles are the main host genetic factors involved in controlling HIV-1 viral load (VL). Nevertheless, HLA diversity has proven a significant challenge in association studies. We assessed how accountin…
View article: Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery
Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery Open
Rationale: Uncertainty regarding the natural history of coronavirus disease (COVID-19) led to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur after hospital discharge may improve asses…
View article: Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO):a randomised controlled trial
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO):a randomised controlled trial Open
BackgroundWe aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for C…
View article: Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial Open
View article: Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels:A Randomized Controlled Trial
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels:A Randomized Controlled Trial Open
Background: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on…
View article: Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 Trial
Tixagevimab/Cilgavimab for Treatment of Hospitalised COVID-19 Patients: A Randomised, Double-Blind, Phase 3 Trial Open
View article: Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) Open
Background/aims Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating COVID-19 Therapeutic Interventions and Vaccines public–private partnership initiated the Therapeutics for Inpatient…
View article: Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19
Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19 Open
BACKGROUND Bamlanivimab, a neutralizing monoclonal antibody given in combination with remdesivir, did not improve outcomes among hospitalized COVID-19 patients based on an early futility assessment. In this final study report, we evaluate …
View article: Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity
Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity Open
Background Understanding the genetic interplay between human hosts and infectious pathogens is crucial for how we interpret virulence factors. Here, we tested for associations between HIV and host genetics, and interactive genetic effects …
View article: Metabolite profiles associated with disease progression in influenza infection
Metabolite profiles associated with disease progression in influenza infection Open
Background We performed metabolomic profiling to identify metabolites that correlate with disease progression and death. Methods We performed a study of adults hospitalized with Influenza A(H1N1)pdm09. Cases (n = 32) were defined by a comp…
View article: A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 Open
Monoclonal antibody LY-CoV555, when coadministered with remdesivir, did not demonstrate efficacy among hospitalized patients who had Covid-19 without end-organ failure. (Funded by Operation Warp Speed and others; TICO ClinicalTrials.gov nu…
View article: The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies
The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies Open
Objectives: The Strategic Timing of AntiRetroviral Treatment (START) and Strategies for Management of Antiretroviral Therapy (SMART) trials demonstrated that ART can partly reverse clinically defined immune dysfunction induced by HIV repli…
View article: Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) Open
Background Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership initiated the Therapeutics for Inpati…
View article: Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial Open
NIAID and NIH. Partial support was provided by the Medical Research Council (MRC_UU_12023/23) and the Danish National Research Foundation.
View article: Influenza Immunoglobulin for Adults Hospitalized with Influenza
Influenza Immunoglobulin for Adults Hospitalized with Influenza Open
View article: 13 HIV-1-specific ADCC following anti-latency therapy and analytical treatment interruption
13 HIV-1-specific ADCC following anti-latency therapy and analytical treatment interruption Open
View article: Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption
Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption Open
There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to eliminate infected cells following reactivation from HIV-1 latency. A potential barrier is that HIV-1-specific ADCC antibodies decline in patients on…
View article: Making Longitudinal Progress in the HIV Care Continuum Within an Urban Veterans Affairs Clinic
Making Longitudinal Progress in the HIV Care Continuum Within an Urban Veterans Affairs Clinic Open
View article: Hepatitis C Treatment at a Veterans Affairs Medical Center After the Availability of Direct-Acting Agents: Things Are Looking Up: Table 1.
Hepatitis C Treatment at a Veterans Affairs Medical Center After the Availability of Direct-Acting Agents: Things Are Looking Up: Table 1. Open
THE EDITOR-The Veterans Health Administration (VHA) is the single largest provider of hepatitis C virus (HCV) care within the United States, with a 5.4% seroprevalence rate for all veterans, which is 3-fold greater than that of the general…